Lawrence Gan
Directeur/Bestuurslid bij Biogen Idec, Inc. (North Carolina)
Profiel
Lawrence Gan is a professional with a doctorate degree from Tulane University.
He currently holds director positions at DuPont Pharmaceuticals Co., Biogen Idec, Inc. (North Carolina), Biotechnology & Pharmaceutical Industries Promotion Office, and Glaxo, Inc. He previously held director positions at Bristol Myers Squibb Co., Biogen, Inc., and DuPont Merck Pharmaceutical Co. He was also a senior director at Millennium Pharmaceuticals, Inc. and Biogen, Inc. Additionally, he served as the President & Chief Executive Officer at Development Center for Biotechnology and Foresee Pharmaceuticals Co., Ltd.
and as the Director-Drug Discovery at Boehringer Ingelheim Pharmaceuticals, Inc.
Actieve functies van Lawrence Gan
| Bedrijven | Functie | Begin |
|---|---|---|
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Directeur/Bestuurslid | - |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Directeur/Bestuurslid | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
| Biotechnology & Pharmaceutical Industries Promotion Office | Directeur/Bestuurslid | - |
Eerdere bekende functies van Lawrence Gan
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOGEN INC. | Directeur/Bestuurslid | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Directeur/Bestuurslid | - |
| BRISTOL-MYERS SQUIBB COMPANY | Directeur/Bestuurslid | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | - |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | - |
Opleiding van Lawrence Gan
| Tulane University (Louisiana) | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| FORESEE PHARMACEUTICALS CO., LTD. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Development Center for Biotechnology
 Development Center for Biotechnology Medical/Nursing ServicesHealth Services The Development Center for Biotechnology of Taiwan is a nonprofit organization co-sponsored by government grants and private donations. It focuses on biotechnology and pharmaceutical industry. The company was founded in 1984 and is headquartered in Taipei, Taiwan. | Health Services |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
| Glaxo, Inc. | |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
| Biotechnology & Pharmaceutical Industries Promotion Office | |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
